The Bayesian analysis of a pivotal pharmacokinetic study

Statistical Methods in Medical Research

Volumn 8, Issue 3, 1999, Pages 195-216

  Rahman, N J ^a   Wakefield, J C ^b   Stephens, D A ^a   Falcoz, C ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE;

BAYES THEOREM; CLINICAL TRIAL; DOSE RESPONSE; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; MATHEMATICAL MODEL; NORMAL HUMAN; POPULATION MODEL; PREDICTION; REVIEW;

EID: 0033461827     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/096228029900800303     Document Type: Review

References (18)

1. Mackie AE, Ventresca GP, Fuller RW, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. British Journal of Clinical Pharmacology 1996; 41: 539-42.
2. Bain BM, Harrison G, Jenkins KD et al. A sensitive radioimmunoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma. Journal of Pharmacological and Biomedical Analysis 1993; 11: 557-61.
3. Wakefield JC, Smith AFM, Racine-Poon A, Gelfand AE. Bayesian analysis of linear and non-linear population models using the Gibbs sampler. Applied Statistics 1994; 41: 201-21.
4. Smith AFM, Roberts GO. Bayesian computation via the Gibbs sampler and related Markov chain Monte Carlo methods. Journal of the Royal Statistical Society B 1993; 55: 3-23.
5. Wakefield JC, Racine-Poon A. An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation. Statistics in Medicine 1995; 14: 971-86.
6. Spiegelhalter D, Thomas A, Best NG. BUGS: Bayesian inference using Gibbs sampling. Medical Research Council Biostatistics Unit, 1996.
7. Wakefield JC. Bayesian individualization via sampling based methods. Journal of Pharmacokinetics and Biopharmaceutics 1996; 24: 103-31.
8. Bennett JE, Racine-Poon A, Wakefield JC. MCMC for nonlinear hierarchical models. In: Gilks WR, Richardson S, Spiegelhalter DJ eds. Markov chain Monte Carlo in Practice. London: Chapman & Hall, 1996: 339-59.
9. Cook RD, Weisberg S. Residuals and influence in regression. Chapman & Hall: London, 1982.
10. Hodges JS. Some algebra and geometry for hierarchical models, applied to diagnostics (with discussion). Journal of the Royal Statistical Society B 1998; 60: 497-536.
11. Dey DK, Chen MH, Chang H. Bayesian approach for non-linear random effects models. Biometrics 1997; 53: 1239-52.
12. Smith AFM, Gelfand AE. Bayesian statistics without tears: a sampling-resampling perspective. The American Statistician 1992; 46: 84-88.
13. Gelfand AE, Hills SE, Racine A, Smith AFM. Illustration of Bayesian inference in normal data models using Gibbs sampling. Journal of the American Statistical Association 1990; 85: 972-85.
14. Geisser S, Eddy W. A predictive approach to model selection. Journal of the American Statistical Association 1979; 74: 153-60.
15. Spiegelhalter DJ, Best NG, Carlin BP. Bayesian deviance, the effective number of parameters, and the comparison of arbitrarily complex models. MRC Biostatistics Unit Technical Report, Cambridge, 1998.
16. Akaike H. Information theory and an extension of the maximum likelihood principle. In Petrov BN, Csake F eds. Second International Symposium on Information Theory. Budapest: Akademiai Kiado, 1973: 267-81.
17. Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/Pharmacokinetics UK Joint Working Party. Drug Information Journal 1995; 29: 1039-48.
18. Lunn DJ, Aarons LJ. Markov chain monte carlo techniques for studying interoccasion and intersubject variability: application to pharmacokinetic data. Applied Statistics 1997; 46: 73-91.